Health & Fitness
Tue, May 3, 2011Mon, May 2, 2011Fri, April 29, 2011Thu, April 28, 2011Wed, April 27, 2011Tue, April 26, 2011Mon, April 25, 2011Fri, April 22, 2011Thu, April 21, 2011Wed, April 20, 2011Tue, April 19, 2011Mon, April 18, 2011Sun, April 17, 2011Fri, April 15, 2011Thu, April 14, 2011Wed, April 13, 2011Tue, April 12, 2011Mon, April 11, 2011MannKind Corporation to Hold 2011 First Quarter Financial Results Conference Call on May 9, 2011
Published in Health and Fitness on Tuesday, April 19th 2011 at 6:07 GMT by Market Wire
VALENCIA, Calif.--([ BUSINESS WIRE ])--MannKind Corporation (Nasdaq: MNKD) will release its 2011 first quarter financial results on Monday, May 9, 2011 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 4:30 PM (Eastern Time) on May 9, 2011. The first quarter conference call was rescheduled from April 25, 2011 in order to provide an opportunity for management to comment on an End-of-Review meeting scheduled to be held with the U.S. Food & Drug Administration during the first week of May. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.
To participate in the live call by telephone, please dial (888) 790-2011 or (312) 470-7327 and use the participant passcode: MANNKIND. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at [ http://www.mannkindcorp.com ].
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (800) 510-9727 or (402) 998-0111. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA(R), is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind is also evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a phase 2 clinical trial. MannKind maintains a website at [ www.mannkindcorp.com ] to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
